Short Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

November 2021 | 84 pages | ID: S8B6C1B63FB9EN
Global Markets Direct

Abstracts

Short Bowel Syndrome (Gastrointestinal) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Drugs In Development, 2021, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 8 and 2 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome - Overview
Short Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Short Bowel Syndrome - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Applied Molecular Transport Inc
enGene Inc
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
Micelle BioPharma Inc
Napo Pharmaceuticals Inc
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
Surrozen Inc
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Worphmed Srl
Zealand Pharma AS
Short Bowel Syndrome - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapiglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vurolenatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 26, 2021: 9 Meters Biopharma presents pharmacokinetic data from phase 1b/2a study with Vurolenatide, currently in phase 2 for short bowel syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
Oct 19, 2021: 9 Meters Biopharma to present data on therapeutic candidate in short bowel syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
Sep 16, 2021: VectivBio announces upcoming investor events
Sep 15, 2021: Orphan Drug Designation application submitted by Jaguar Health subsidiary for crofelemer for short bowel syndrome with intestinal failure accepted for review by European Medicines Agency
Sep 13, 2021: Providing innovative treatment options for patients with intractable rare disease short bowel syndrome
Sep 09, 2021: Zealand Pharma presents data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in both small and large intestines of animal models - in contrast to short-acting GLP-2
Aug 19, 2021: Zealand Pharma announces first patient dosed in EASE-SBS 4 phase 3b trial assessing glepaglutide in patients with short bowel syndrome
Jun 29, 2021: Zealand Pharma to present data on glepaglutide at the 17th Congress of the Intestinal Rehabilitation and Transplantation Association (CIRTA)
Jun 15, 2021: VectivBio announces first patient dosed in metabolic balance study of apraglutide in colon-in-continuity patients with short bowel syndrome with intestinal failure
Jun 14, 2021: 9 Meters announces initiation of phase 2 VIBRANT study of Vurolenatide for short bowel syndrome
May 17, 2021: 9 Meters Biopharma receives USAN approval to use the designated nonproprietary name Vurolenatide for its long-acting GLP-1 agonist for short bowel syndrome
Apr 07, 2021: Hanmi's short bowel syndrome drug gets FDA fast-track status
Mar 15, 2021: 9 Meters Biopharma hosting key opinion leader webinar on short bowel syndrome and NM-002 program update
Feb 03, 2021: VectivBio announces first patient dosed in pivotal phase 3 trial of Apraglutide for the treatment of short bowel syndrome
Feb 01, 2021: 9 Meters Biopharma announces Research & Development Day on short bowel syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Short Bowel Syndrome, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Short Bowel Syndrome - Pipeline by 9 Meters Biopharma Inc, 2021
Short Bowel Syndrome - Pipeline by Applied Molecular Transport Inc, 2021
Short Bowel Syndrome - Pipeline by enGene Inc, 2021
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, 2021
Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, 2021
Short Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, 2021
Short Bowel Syndrome - Pipeline by OPKO Health Inc, 2021
Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, 2021
Short Bowel Syndrome - Pipeline by Surrozen Inc, 2021
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
Short Bowel Syndrome - Pipeline by VectivBio Holding AG, 2021
Short Bowel Syndrome - Pipeline by Worphmed Srl, 2021
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, 2021
Short Bowel Syndrome - Dormant Projects, 2021
Short Bowel Syndrome - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021